Your browser doesn't support javascript.
loading
Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.
Klinghammer, Konrad; Politz, Oliver; Eder, Theresa; Otto, Raik; Raguse, Jan-Dirk; Albers, Andreas; Kaufmann, Andreas; Tinhofer, Ingeborg; Hoffmann, Jens; Keller, Ulrich; Keilholz, Ulrich.
Afiliación
  • Klinghammer K; Department of Hematology and Medical Oncology, Charité, Berlin, Germany.
  • Politz O; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany.
  • Eder T; Department of Radiooncology and Radiotherapy, Charité University Hospital, Berlin, Germany.
  • Otto R; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) Partner Sites, Berlin, Germany.
  • Raguse JD; WBI, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Albers A; Department of Maxillio-Facial Surgery, Fachklinik Hornheide, Münster, Germany.
  • Kaufmann A; Department of ENT, Charité, Berlin, Germany.
  • Tinhofer I; Department of Gynaecology, Charité, Berlin, Germany.
  • Hoffmann J; Department of Radiooncology and Radiotherapy, Charité University Hospital, Berlin, Germany.
  • Keller U; Experimental Pharmacology & Oncology GmbH, Berlin, Germany.
  • Keilholz U; Department of Hematology and Medical Oncology, Charité, Berlin, Germany.
Oncotarget ; 11(41): 3688-3697, 2020 Oct 13.
Article en En | MEDLINE | ID: mdl-33110476
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncotarget Año: 2020 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncotarget Año: 2020 Tipo del documento: Article País de afiliación: Alemania